Alumis Inc./$ALMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alumis Inc.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
Ticker
$ALMS
Sector
Health
Primary listing
Employees
183
Headquarters
Website
Alumis Inc. Metrics
BasicAdvanced
$447M
-
-$8.31
-
-
Price and volume
Market cap
$447M
52-week high
$10.49
52-week low
$2.76
Average daily volume
741K
Financial strength
Current ratio
3.731
Quick ratio
3.453
Long term debt to equity
17.429
Total debt to equity
18.941
Profitability
EBITDA (TTM)
-351.452
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,974.51%
Operating margin (TTM)
-2,039.73%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-101.07%
Return on equity (TTM)
-247.05%
Valuation
Price to revenue (TTM)
10.289
Price to book
1.4
Price to tangible book (TTM)
1.4
Price to free cash flow (TTM)
-0.611
Free cash flow yield (TTM)
-163.65%
Free cash flow per share (TTM)
-7.086
Growth
Earnings per share change (TTM)
-88.96%
Bulls say / Bears say
Alumis completed its merger with ACELYRIN in May 2025, creating a combined company with a pro forma cash position of approximately $737 million and extending its financial runway into 2027 (Nasdaq).
The company announced the completion of patient enrollment in its pivotal Phase 3 ONWARD program for ESK-001 with over 1,700 participants, positioning it to report topline data in early Q1 2026 (Nasdaq).
At ACTRIMS 2025, Alumis presented Phase 1 data demonstrating that A-005, its CNS-penetrant TYK2 inhibitor, successfully crosses the blood–brain barrier and is well tolerated, supporting a Phase 2 MS trial initiation in H2 2025 (BioSpace).
Alumis reported a net loss of $294.2 million for the year ended December 31, 2024, driven by R&D expenses of $265.6 million, highlighting a high cash burn and substantial operating losses (BioSpace).
Topline results from the pivotal Phase 3 ONWARD trial for ESK-001 are not expected until Q1 2026, leaving the stock exposed to prolonged clinical and regulatory risk without near-term catalysts (BioSpace).
A surprise cash bid by Concentra Biosciences for ACELYRIN introduces material risk to the completion of the Alumis–ACELYRIN merger, potentially undermining anticipated strategic and financial benefits (FierceBiotech).
Data summarised monthly by Lightyear AI. Last updated on 25 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alumis Inc. stock?
Alumis Inc. (ALMS) has a market cap of $447M as of August 09, 2025.
What is the P/E ratio for Alumis Inc. stock?
The price to earnings (P/E) ratio for Alumis Inc. (ALMS) stock is 0 as of August 09, 2025.
Does Alumis Inc. stock pay dividends?
No, Alumis Inc. (ALMS) stock does not pay dividends to its shareholders as of August 09, 2025.
When is the next Alumis Inc. dividend payment date?
Alumis Inc. (ALMS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alumis Inc.?
Alumis Inc. (ALMS) does not currently have a Beta indicator.